Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200–400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediate-release formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin’s effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.

background

/pdf/role-of-guaifenesin-in-the-management-of-chronic-bronchitis-1aje8rnu9b.pdf

Effective antitussive agent in the treatment of cough in childhood.

Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

A Clinical Evaluation of the Effectiveness of Robitussin* in Chronic Cough* *

Pharmaka, welche die physikochemischen Eigenschaften des Bronchialsekretes andern und die Expektoration fordern, werden seit jeher in der Behandlung von Erkrankungen des Respirationstraktes angewandt, obwohl die Kenntnisse ihrer Wirkungsweise mangelhaft sind und ihr gunstiger therapeutischer Wert selten objektiv erfast wird.

Effective antitussive agent in the treatment of cough in childhood.

Citations

Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

A Clinical Evaluation of the Effectiveness of Robitussin* in Chronic Cough* *

Klinisch-pharmakologische Studien zur Bronchosekretolyse

Related Papers (5)

New possibilities in appropriate cough therapy

Clinical experiences with the antitussive agent megadrol

Clinical experiences with a new antitussive agent

Potential new cough therapies.

Drugs to suppress cough.